U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula 3C6H11O7.Fe.3H2O
Molecular Weight 695.333
Optical Activity UNSPECIFIED
Defined Stereocenters 12 / 12
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERRIC GLUCONATE TRIHYDRATE

SMILES

O.O.O.[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O

InChI

InChIKey=QUIAVNOOCZTWEL-AGRODQNPSA-K
InChI=1S/3C6H12O7.Fe.3H2O/c3*7-1-2(8)3(9)4(10)5(11)6(12)13;;;;/h3*2-5,7-11H,1H2,(H,12,13);;3*1H2/q;;;+3;;;/p-3/t3*2-,3-,4+,5-;;;;/m111..../s1

HIDE SMILES / InChI

Description

Gluconic acid is a natural compound produced from glucose through a simple dehydrogenation reaction catalysed by glucose oxidase. Gluconic acid and its salts are used in the formulation of food, pharmaceutical and hygienic products.

Originator

Hlasiwetz, H.|Habermann, J.
6

Approval Year

1975
63

Targets

Primary TargetPharmacologyConditionPotency
Ferritin light chain
6
Binding Agent
1,076

Conditions

ConditionModalityTargetsHighest PhaseProduct
Iron deficiency anemia
52
 Primary
Approved
8,583
Ferrlecit

Cmax

ValueDoseCo-administeredAnalytePopulation
12.9 μg/mL
1.5 mg/kg single, intravenous
 GLUCONATE ION plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
95 μg × h/mL
1.5 mg/kg single, intravenous
 GLUCONATE ION plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
1.5 mg/kg single, intravenous
 GLUCONATE ION plasma
Homo sapiens

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2,252
inhibitor
2,438
inhibitor
2,217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C19
2,057

CYP1A2
2,153

CYP19A1
429

Drug as perpetrator​

Tox targets

PubMed

Patents

JP2000212599A
6
JP2000279106A
7
JP2000512663A
47
JP2002167429A
6
JP2002167575A
6
JP2002255720A
6
JP2003081778A
17
JP2004026770A
6
JP2004182698A
10
JP2004516233A
21
JP2004523616A
17
JP2005097121A
6
JP2005278522A
6
JP2006188648A
6
JP2008031333A
6
JP2008220388A
6
JP2009082067A
6
JP2009108065A
6
JP2009126799A
6
JP2009526755A
475
JP2010138170A
6
JP2010502559A
6
JP2011519292A
9
JP3333202B2
6
JP3369179B2
6
JP4098830B2
6
JP4663983B2
6
JPH01100039A
6
JPH01104006A
6
JPH01157491A
6
JPH02109989A
6
JPH02131545A
6
JPH0224564A
6
JPH03206040A
6
JPH03262491A
6
JPH03294392A
6
JPH0387152A
6
JPH04156948A
7
JPH04180765A
6
JPH0431382A
6
JPH05140590A
6
JPH05176694A
6
JPH05177134A
6
JPH05260979A
6
JPH05284985A
6
JPH06230003A
6
JPH06277093A
7
JPH0688096A
6
JPH07101792A
6
JPH07173003A
6
JPH0776520A
6
US20030216566
6
US8058076
6
WO2003098564A1
6

Sample Use Guides

In Vivo Use Guide
8 weeks of IV ferric gluconate 125 mg weekly
Route of Administration: Intravenous
In Vitro Use Guide
The effect of iron(III)-gluconate (Ferlixit) at various concentrations on the malondialdehyde production in isolated rat liver mitochondria was studied. Concentratiors of iron as low as 100 uM are able to elicit a significant enhancement of lipid peroxidation. process.
ACTIVE MOIETY
Structure of Gluconic Acid
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966